RxDoctor Payments Data

Christina Sawyer, MD

Internal Medicine · Key West, FLNPI 1710372578

Payments from drug & device makers

$701in general payments, 2019–2025

Across 31 payments — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$184
  • Exact Sciences$116
  • Lilly USA, LLC$102
  • Novo Nordisk$54
  • Almatica Pharma LLC$52
  • Pfizer$41
  • plus $152 from 7 others

What the payments were for

  • Food & beverage$701100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$701 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$111,917
Medicare patients
643
Services billed
2,187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$56,667
TrulicityDulaglutide76$51,868
JardianceEmpagliflozin32$37,476
JanuviaSitagliptin Phosphate36$27,171
OzempicSemaglutide29$26,233
XareltoRivaroxaban14$23,430
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$21,983
MounjaroTirzepatide14$20,336
MyrbetriqMirabegron17$14,468
Breo ElliptaFluticasone/Vilanterol23$8,660
Praluent PenAlirocumab12$5,746
Testosterone25$3,312
Albuterol Sulfate HfaAlbuterol Sulfate70$2,522
Atorvastatin Calcium214$2,490
Ezetimibe19$2,346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$102$72,20490 claims
PfizerEliquis$41$56,66756 claims
Boehringer IngelheimJardiance$15$37,47632 claims
GSKTrelegy Ellipta, Breo Ellipta$34$30,64350 claims
Novo NordiskOzempic$54$26,23329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Key West

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →